ArticlePediatric nephrology (Berlin, Germany)2009
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.
Article in Pediatric nephrology (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 4 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Prevalence of histopathological subtypes associated with steroid-resistant nephrotic syndrome in children: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Development of a Conceptual Model for the Patient Experience of Focal Segmental Glomerulosclerosis (FSGS): A Qualitative Targeted Literature Review.Advances in therapy · 2023Pooled it
- Current and Potential Approaches for Defining Disease Signatures: a Systematic Review.Journal of molecular neuroscience : MN · 2019Pooled it
- The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis.International urology and nephrology · 2014Pooled it
- Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis.Pediatric nephrology (Berlin, Germany) · 2013Trial
- Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.Kidney international reports · 2026Article
- Predictors of Heart Failure in Pediatric Patients with End-Stage Kidney Disease Secondary to Nephrotic Syndrome.Medicina (Kaunas, Lithuania) · 2026Article
- Remission rates and long-term outcomes of relapsed pediatric nephrotic syndrome: cyclophosphamide vs. cyclosporin A.Pediatric nephrology (Berlin, Germany) · 2026Article
- Review
- Challenging Clinical Practice Guideline Definitions in Childhood Nephrotic Syndrome.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Efficacy of Calcineurin Inhibition in Children With Steroid-Resistant Nephrotic Syndrome.Kidney international reports · 2025Article
- Shear wave elastography for assessing kidneys in pediatric patients with primary nephrotic syndrome.Insights into imaging · 2025Article
- Outcomes and prognostic factors in childhood-onset steroid-resistant nephrotic syndrome: a retrospective single-center study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Comparative Evaluation of Urinary Biomarkers in Wilms Tumor Survivors and Children with Chronic Kidney Disease.International journal of molecular sciences · 2025Article
- Subclinical systolic dysfunction in children with steroid-resistant nephrotic syndrome identified by speckle tracking echocardiography.BMC pediatrics · 2025Article
- Special Issue "Nephrotic Syndrome: Pathomechanism, Diagnostics, and Novel Treatment Options".Biomedicines · 2024Article
- Clinical characteristics and prognosis of steroid-resistant nephrotic syndrome in children: a multi-center retrospective study.Italian journal of pediatrics · 2024Article
- Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study.Pediatric nephrology (Berlin, Germany) · 2024Article
- Novel mutation patterns in children with steroid-resistant nephrotic syndrome.Clinical kidney journal · 2024Article
- Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term outcome of idiopathic steroid-resistant nephrotic syndrome was retrospectively studied in 78 children in eight centers for the past 20 years. Median age at onset was 4.4 years (1.1-15.0 years) and the gender ratio was 1.4. Median follow-up period was 7.7 years (1.0-19.7 years). The disease in 45 patients (58%) was initially not steroid-responsive and in 33 (42%) it was later non-responsive. The main therapeutic strategies included administration of ciclosporine (CsA) alone (n = 29; 37%) and CsA + mycophenolate mofetil (n = 18; 23%). Actuarial patient survival rate after 15 years was 97%. Renal survival rate after 5 years, 10 years and 15 years was 75%, 58% and 53%, respectively. An age at onset of nephrotic syndrome (NS) > 10 years was the only independent predictor of end-stage renal disease (ESRD) in a multivariate analysis using a Cox regression model (P < 0.001). Twenty patients (26%) received transplants; ten showed recurrence of the NS: seven within 2 days, one within 2 weeks, and two within 3-5 months. Seven patients lost their grafts, four from recurrence. Owing to better management, kidney survival in idiopathic steroid-resistant nephrotic syndrome (SRNS) has improved during the past 20 years. Further prospective controlled trials will delineate the potential benefit of new immunosuppressive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.